Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

A chip addict who ballooned to 280 pounds scoffing down four bags a day managed to lose half her body weight naturally — ...

Several studies have found patients taking GLP-1 medications like Wegovy and Mounjaro regain weight, sparking fresh health advice from experts.